Evidence map›Paper›PMID 20538003›Full record

ArticleJournal of molecular and cellular cardiology2010

EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB andMKK7/JNK/AP-1 signaling.

Balachandar Venkatesan, Anthony J Valente, Sumanth D Prabhu, Prakashsrinivasan Shanmugam, Patrice Delafontaine, Bysani Chandrasekar

Open access · greenAbstract read
In one paragraph

Article in Journal of molecular and cellular cardiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Novel Evidence of Acute Kidney Injury in COVID-19.Journal of clinical medicine · 2020
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Balachandar VenkatesanResearch Service, Southeast Louisiana Veterans Health Care System, New Orleans, LA 70161, USA.
Anthony J Valente
Sumanth D Prabhu
Prakashsrinivasan Shanmugam
Patrice Delafontaine
Bysani Chandrasekar
Southeast Louisiana Veterans Health Care System · USTulane University · USThe University of Texas Health Science Center at San Antonio · USVeterans Health Administration · US

Funding

Insulin-Like Growth Factor-1and AtherosclerosisR01HL070241 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI PATRICE DELAFONTAINE · 2003 to 2026
$10.1M
ANGIOTENSIN II, IGF-1 AND SKELETAL MUSCLE ATROPHYR01HL080682 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI DELAFONTAINE, PATRICE · 2007 to 2015
$3.3M
The Role of Interleukin-18 in Myocardial Hypertrophy and FailureR01HL086787 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BYSANI, CHANDRASEKAR · 2009 to 2013
$1.8M
Role of Glutathione S-Transferase P in Heart FailureR01HL099014 · NHLBI · UNIVERSITY OF LOUISVILLE · PI PRABHU, SUMANTH D · 2010 to 2013
$1.5M
NHLBI NIH HHS HL-70241NHLBI NIH HHS HL-80682NHLBI NIH HHS HL-86787NHLBI NIH HHS R01 HL070241NHLBI NIH HHS R01 HL080682NHLBI NIH HHS R01 HL086787NHLBI NIH HHS R01 HL099014
6 · The paper itself

Abstract

The transmembrane glycoprotein extracellular matrix metalloproteinase inducer (EMMPRIN), and the pleiotropic proinflammatory cytokine interleukin (IL)-18, play critical roles in myocardial remodeling, by inducing matrix degrading metalloproteinases (MMPs). Previously we showed that IL-18 induces EMMPRIN expression in cardiomyocytes via MyD88/IRAK4/TRAF6/JNK-dependent Sp1 activation. Here in reciprocal studies we demonstrate that EMMPRIN is a potent inducer of IL-18 transcription, protein expression and protein secretion in primary mouse cardiomyocytes. We show for the first time that EMMPRIN stimulates the activation of NF-kappaB, AP-1, CREB, and ATF-2 in cardiomyocytes, and induces IL-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB and MKK7/JNK/AP-1 signaling. Moreover, EMMPRIN induces robust time-dependent induction of various MMP mRNAs. EMMPRIN also induces the mRNA of TIMPs 1 and 3, but in a delayed fashion. These results suggest that IL-18-induced EMMPRIN expression may favor net MMP expression and ECM destruction, and thus identify both as potential therapeutic targets in countering adverse myocardial remodeling.

Indexed as

AnimalsBasiginCells, CulturedEnzyme-Linked Immunosorbent AssayI-kappa B KinaseInterleukin-18MaleMAP Kinase Kinase 7MiceMice, Inbred C57BLMyocytes, CardiacNeuropeptidesNF-kappa BPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktrac1 GTP-Binding ProteinBasiginBsg protein, mouseI-kappa B KinaseInterleukin-18Map2k7 protein, mouseMAP Kinase Kinase 7NeuropeptidesNF-kappa BPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktrac1 GTP-Binding ProteinRac1 protein, mouserac GTP-Binding ProteinsTranscription Factor AP-1

Identifiers

PMID20538003
PMCPMC3042694
OpenAlexW1971940860

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.